Pál Gyulavári

NRF2-regulated cell cycle arrest at early stage of oxidative stress response mechanism

Margita Márton, Nikolett Tihanyi, Pál Gyulavári et al. · PLoS ONE · 2018 · 31 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Discovery of <i>N</i>-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

István Szabadkai, Robert Torka, Rita Garamvölgyi et al. · Journal of Medicinal Chemistry · 2018 · 25 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Bálint Szokol, Pál Gyulavári, Ibolya Kurkó et al. · ACS Medicinal Chemistry Letters · 2014 · 14 citations · Full text

Medicine, Oncology, Pharmacology +14

Synthesis, characterization and systematic comparison of FITC‐labelled GnRH‐I, ‐II and ‐III analogues on various tumour cells

József Murányi, Pál Gyulavári, Attila Varga et al. · Journal of Peptide Science · 2016 · 13 citations

Pharmacy, Oncology, Pharmacology +17

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

Attila Varga, Pál Gyulavári, Zoltán Greff et al. · PLoS ONE · 2015 · 11 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16